本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields GIEßEN, GERMANY - Newsaktuell - 17 January 2025 - The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research. The nomination portal (www.broermann-award.org/nomination/) is open until March 1, 2025. At one million euros, the prize is more valuable than the Nobel Prize for Medicine, making it one of the most highly endowed awards for medical research worldwide. The international Broermann Medical Innovation Award recognizes research results that demonstrate a high level of innovation for clinical application and thus have the potential to improve the lives and health of millions of people worldwide. The prize is aimed at scientists whose research has been pioneering in the fields of medicine, biotechnology, or related sciences. The Broermann Medical Innovation Award was established in 2024 to honor the vision and commitment of Dr. Bernard große Broermann, the founder of the Asklepios Kliniken. The Broermann gemeinnützige GmbH sponsors the award, and the University Hospital Giessen and Marburg (UKGM) manages the organization. "With this award, we want to honor groundbreaking medical discoveries and highlight those whose research brings real improvements in the prevention or treatment of diseases," says Prof. Werner Seeger, Chairman of the Award Committee. For the Medical Director of the UKGM, Prof. Friedrich Grimminger, the unique prize reflects the clear conviction of the company founder: "Scientific excellence in medicine is always an international team effort, but without the genius of individual researchers, networks are limited in their impact. These key players and drivers of medical innovation should be promoted and recognized worldwide." Nomination process and deadlines Nominations for the Broermann Medical Innovation Award can be submitted until March 1, 2025. The incumbent Hessian Minister President will present the award in December 2025 at the Hessian State Chancellery in Wiesbaden. Further information on the award, the nomination criteria, and the selection process can be found at www.broermann-award.org. The issuer is solely responsible for the content of this announcement.
BANGKOK, THAILAND - Media OutReach Newswire - 27 December 2024 - The Ministry of Higher Education, Science, Research, and Innovation (MHESI), through the National Innovation Agency (Public Organization) or NIA, is forging ahead to support high-potential Thai startups and SMEs in the medical and health innovation sectors, granting them access to Germany, one of Europe's largest and most significant MedTech markets. As part of the 'Digital Innovation Business Development Programme for Connecting to International Markets and Funding in Europe,' NIA has selected eight outstanding Thai medical and health innovation startups and SMEs that have received prior NIA backing. These companies will showcase their cutting-edge innovations at Medica 2024 in the Federal Republic of Germany. The initiative aims to propel Thai medical innovations to global prominence and establish stronger footholds in the European market. Medica 2024 offers a critical platform for connecting Thai innovators with international opportunities, reinforcing Thailand's reputation as a global leader in medical and health innovation. Dr Krithpaka Boonfueng, Executive Director of the National Innovation Agency (Public Organisation), along with Professor Emeritus Dr Sirirurg Songsivilai, Chairman of the Board of Science, Research, and Innovation Promotion (GSRI), and a delegation of executives and staff from NIA, visited the exhibition booth showcasing the achievements of eight medical and health innovation startups supported by NIA. The visit took place at the Medica 2024 event in the Federal Republic of Germany. Dr. Krithpaka Boonfueng, Executive Director of the National Innovation Agency (Public Organization) or NIA, stated that NIA, in its role as a 'Focal Conductor of Innovation,' is dedicated to nurturing and enhancing the capabilities of Thai innovators to achieve sustainable growth. This commitment is guided by the '4G Approach': Groom: Fostering and strengthening the potential of Thai innovators. Grant: Providing financial mechanisms to develop and scale innovative businesses to market readiness. Growth: Accelerating the expansion of both startups and SMEs in the innovation ecosystem. Global: Propelling Thai innovators onto the international stage. Thailand's medical industry, a standout sector, benefits from one of the world's top-ranking healthcare systems. The global MedTech market is projected to soar to 775.8 billion US dollars by 2029, with Germany emerging as a particularly promising market. Germany's long-standing role as host of the world-renowned Medica trade fair for over 40 years underscores its importance. Recognised by experts as the largest medical trade exhibition globally, Medica attracts more than 6,100 exhibitors from 69 countries, solidifying its status as a pivotal platform for the medical and healthcare sectors. Dr Krithpaka added that the NIA is proud to participate in Medica 2024 under the theme 'Meet Health. Future. People,' hosted in the Federal Republic of Germany. As part of this prestigious event, eight outstanding Thai medical and healthcare innovation startups and SMEs, selected through a rigorous process, will showcase their pioneering solutions. These include: Eidy: A large language model (LLM) tailored for medical applications, distinguished by its specialised terminology and physician-like reasoning. It holds potential for developing chatbots designed to address specific medical queries. Ravis Technology: A platform for managing clinical research and data related to biopharmaceuticals, medical devices, and drugs. By leveraging technology to streamline data management, it saves time and costs. Pose Intelligence: A medical equipment management platform for hospitals, providing precise inventory control and central supply management. It reduces redundancy and minimises errors with its efficient systems. SOS Care: An innovative wound dressing made from silk protein combined with carboxymethyl cellulose (CMC) and glycerin. This flexible dressing promotes collagen production, accelerating wound healing. POPOLO: A device designed to band oesophageal varices caused by abnormal blood flow to the liver. This innovation enhances accessibility for Thai patients and reduces mortality rates. Orthopeasia: A cutting-edge platform for designing and producing spinal disc replacements using specialised software. Its innovation simplifies surgical procedures, ensuring smaller incisions, faster operations, and improved convenience for both surgeons and patients. BRE: A revolutionary two-step bathing sheet that eliminates the need for water and soap, providing a practical solution for patients unable to bathe, significantly enhancing their quality of life. Aquatrek Solution: A water treadmill, an advanced hydrotherapy device ideal for reducing the risks associated with exercise, particularly for the elderly. It minimises joint strain while supporting body weight, making it highly effective for rehabilitation and therapy. These eight groundbreaking innovations have garnered considerable interest from partners and potential collaborators across the United States, Europe, and Canada, seeking to exchange technologies and customer bases. Collaborative research opportunities, such as co-publishing with German academics, hosting researcher exchange programmes, or licensing specific or complete production technologies for German manufacturing, could significantly bolster the credibility of Thai medical devices. Research partnerships are a gateway to greater acceptance in the European market. Furthermore, studying attendee and exhibitor profiles at Medica 2024 offers invaluable insights for refining Thai innovations and devising strategic marketing approaches. These initiatives could stimulate investments, foster business matchmaking, and pave the way for cross-border collaborations, driving future advancements in medical innovation. Ms Maleepan Phasupong, from Ravis Technology Co Ltd, a developer of clinical research management platforms, shared her perspective on being selected to participate in the global medical and health innovation showcase Medica 2024. She highlighted that this prestigious event provided invaluable insights into the European market's overall needs, particularly in the realms of digital solutions, health and physical care devices, and diagnostic tools. Beyond helping Thai startups align their innovations with market demands, it serves as a pivotal starting point for achieving real business partnerships. By showcasing Thailand's research strengths, especially to Western countries increasingly interested in collaborative research with Thailand, the event bolstered international recognition. This growing interest is particularly evident in the West, where there is a notable trend towards exploring research partnerships in Thailand. During the event, the company secured discussions with five potential partners and clients, with follow-ups already underway. German STEM researchers, in particular, have expressed interest in exchanges with Thailand to reduce costs associated with services and production within Europe, such as clinical research expenses or medical device manufacturing. This highlights the tangible opportunities created through platforms like Medica, not only for networking but also for fostering deeper international collaboration and reducing operational costs. Mr Thanatpant Manosittisak of SOS Care Co Ltd, developer of silk-protein wound dressings, emphasised that Thai medical and health startups and SMEs have strong potential to thrive in global markets if provided with adequate support in terms of funding, resources, and technological development. He pointed out that Thailand's lower production costs, compared to developed nations, present a competitive advantage. However, government support is crucial to propel these startups and SMEs into forming international collaborations and expanding their market and business networks. Such backing enhances their credibility and strengthens confidence in the quality and innovation of Thai products on the global stage. Mr Thanatpant expressed hope that participating in Medica 2024 would enable his company to secure distributors across Europe, Asia, and the Middle East, thereby driving further international market expansion. Hashtag: #NIA The issuer is solely responsible for the content of this announcement.
Experts from Various Fields Gather to Discuss Cutting-Edge Medical Topics "Innovation+ Finance" Boosts Development of Medical Startups in Hong KongHONG KONG SAR - Media OutReach Newswire - 16 December 2024 - The Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) and College of Engineering, City University of Hong Kong proudly hosted the inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) on December 12th. This flagship event brought together leading experts from industry, university, and research sectors to foster cross-disciplinary integration and collaboration among experts, to explore the path of innovation in the healthcare industry. During the summit, COCHE signed an MoU with Shanghai Innovation Bank to establish a partnership focused on fostering medical innovation. MoU Signing Ceremony Bringing Together Leaders from Industry, University and Research The inaugural International Cerebro-Cardiovascular Medical Innovation Summit was held at City University of Hong Kong, featuring prominent representatives from industry, university, and research sectors in the medical field from both Mainland and Hong Kong to explore and drive forward the frontiers of medical innovation. At the opening ceremony, Ms. Gracie NG, Chief of Staff and Acting Chief Corporate Development Officer, HKSTP, Prof. Johnny Chung Yin HO, Associate Vice-President (Enterprise), and Prof. LU Jian, Dean, College of Engineering, City University of Hong Kong, delivered speeches. Ms. Gracie NG said: "The collaboration between COCHE and Shanghai Innovation Bank is of great significance to the bank's business, greatly filling the industry gap in the cooperation between finance and the innovation technology sector. The importance of financial support for the success of startups is also fully reflected in this collaboration. The 'innovation + finance' cooperation model will promote the development of the Hong Kong technology innovation ecosystem." Prof. Johnny Chung Yin HO points: "City University of Hong Kong is the first local university in Hong Kong to promote the concept of 'One Health', in which we established the Institute of Digital Medicine in April of this year. The institute is dedicated to leveraging the university's research strengths in engineering, life sciences, artificial intelligence, and data science to provide innovative digital healthcare solutions. CityU will continue to cultivate more innovation and technology talent through the HK Tech 300 Program and the CityUHK Academy of Innovation, transforming the university's research outcomes into practical applications. Additionally, it will collaborate with the College of Engineering and COCHE to promote innovation and advancements in the healthcare sector. " Prof. LU Jian welcomed the guests on behalf of the summit's co-organizers, in which he mentioned: "The field of engineering plays a crucial role in connecting technological theory with real-world product applications. I am pleased that this summit provides a platform for experts and scholars from various fields to converge, communicate, and collaborate. The summit aims to promote interdisciplinary collaboration, transforming innovative ideas into practical solutions, and dedicate the contribution to the advancement of healthcare outcomes. " Collaboration with Shanghai Innovation Bank to nurture medical innovation During the opening ceremony, COCHE signed an MoU with Shanghai Innovation Bank, establishing a partnership in fostering the "New Quality Productive Forces" through the "innovation + finance" model. The MoU outlines a collaborative framework whereby COCHE will serve as a platform to facilitate the integration of technology innovation resources, including the business matching of relevant startups. This partnership seeks to establish a new win-win cooperation model for innovative enterprise incubation, merging science and technology with finance. Shanghai Innovation Bank will offer tailored debt financing, eco-system connections and various business empowerment initiatives for emerging medical technology startups and support their globalization strategies through collaborative efforts. Prof. Kannie WY CHAN, Centre Director of COCHE, commented: "Funding has always been a significant challenge for the translation of technical solutions into clinical use in Hong Kong. This collaboration provides a much-needed boost to our medical research efforts. By leveraging the 'innovation + finance' model, we can enhance the transformation of research outcomes, generate greater economic benefits, and advance the development of medical new quality productivity forces." Explore Pathways Towards Forward-Thinking Medical Innovation The summit featured two main sessions: "Digital Medical Innovations in Community" and "Ecosystem for Medical Innovations" where experts shared insights and engaged in discussions on a range of topics. Prof. LU Xiongwen, Dean of School of Management at Fudan University, delivered a plenary speech titled "Overview of Empowering Healthcare Enterprises through Management in China and Globally", where he mentioned: "The development of the health industry has enormous demand, and the entire sector is poised for significant growth. Whether in the field of cardiovascular health or the broader health industry, management empowerment is essential. From scientific and technical personnel to product development, and then to industrialization and marketization, the entire process requires management intervention to enable innovation and technological development through effective management. " Prof. Bryan YAN, Head of Division of Cardiology (Academic Affairs) at the Faculty of Medicine of The Chinese University of Hong Kong, delivered a keynote speech on "Stroke Prevention with Innovation". Prof. Bryan YAN highlights innovative strategies, like AI modelling and ECG monitoring for early detection and intervention, that can lead to stroke prevention being greatly enhanced. " By establishing health monitoring systems and raising awareness of risk factors, the goal is to identify individuals at risk of stroke as soon as possible. Integrating these technological solutions can significantly improve prevention efforts, leading to better health outcomes and a lower incidence of strokes." Prof. Bryan YAN said. In addition to serving as a platform for medical and university exchanges, the summit also arranged pitching sessions for different start-up incubated by COCHE to showcase their innovative medical technologies. Among them, Pyrocks Ultrasonics Company mainly produces an AI-Powered Ultrasound Patch for CVD Risk Assessment. This innovation can revolutionize the way people face and manage CVD by screening groups with varying levels of CVD risk, providing timely protection against CVD-related deaths. The inaugural International Cerebro-cardiovascular Medical Innovation Summit (ICMIS) successfully brought together experts, scholars, and industry representatives from various fields to discuss cutting-edge medical topics and promote multi-party collaboration. The summit organizer, COCHE, has taken the lead in the path of cardiovascular and cerebrovascular medical innovation, establishing a partnership with the Board of Directors of Yan Chai Hospital in Hong Kong. Through COCHE's innovative medical technologies and products, health screening activities have been conducted in multiple communities across Hong Kong, enabling residents to become aware of potential health risks in a timely manner. COCHE believes that the future of the healthcare sector relies on interdisciplinary collaboration, and the successful execution of this summit is expected to contribute valuable insights and support for the development of cardiovascular health medicine. Hashtag: #Cerebrocardiovascular#MedicalInnovationSummit #ICMISThe issuer is solely responsible for the content of this announcement.The 1st International Cerebro-cardiovascular Medical Innovation Summit (ICMIS)The International Cerebro-cardiovascular Medical Innovation Summit, a premier gathering of university, clinical, regulatory, industrial, financial, and other diverse fields, featuring leading experts from international realms. This summit aims to serve as a platform for exchange and sharing, fostering dialogue and collaborations among experts across various domains, to explore the path of innovation in the healthcare industry and drive forward the frontiers of medical innovation. Website: https://www.icmis2024.com Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE)In collaboration with the University of Oxford and the Karolinska Institutet, Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE) was established under City University of Hong Kong in 2020. The COCHE, supported financially by Innovation and Technology Commission (ITC), was admitted to Inno-Health cluster of InnoHK Programme which is a major R&D initiative of the Hong Kong Special Administrative Region Government. We are developing flexible sensing, biomedical and molecular imaging, nano-biosensing, and AI in health with the focus on innovative wearables that collect key vital signs, including but not limited to continuous blood pressure and electrocardiogram signals on an unobtrusive and real-time basis. The collected data is transmitted for further analysis and integration with other biomarkers, paving the way for the early detection and diagnosis of possible acute cerebro-cardiovascular diseases. Website: https://www.hkcoche.org/
SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- This golden October, great minds gathered to embark on a new chapter of innovation. The 2024 Oriental Conference of Interventional Neurovascology (OCIN 2024), a premier event in neurovascular treatment, was held successfully from October 25th to 27th at the Shanghai International Convention Center. Organized by the Shanghai Medical Association and the Shanghai Stroke Specialty Branch, the conference brought together leading experts and industry pioneers to discuss the latest advances and insights in neurovascular care. Live broadcast of the animal experiment for remote interventional neurosurgery/ Market Launch Ceremony for the PANVIS-A™ Neurovascular Interventional Robotic System Making its third appearance at OCIN, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. (abrobo) adhered to the theme " Revitalizing Vessels at Your Fingertips " to design a futuristic exhibit. The immersive booth featured a hands-on training center, providing attendees with the chance to explore the company's latest breakthroughs up close. At the heart of the showcase was the PANVIS series of PAN-vascular interventional robotic systems, which became the focal point of the conference. Breaking Surgical Barriers: The PANVIS Series of Pan-vascular Interventional Robotic system Enhances Precision in Medical Care The success of an intervention depends on precision, stability, and alignment with surgeons' operational habits. On August 26th, 2024, the PANVIS-A™ Neurovascular Interventional Robotic System, developed independently by Shenzhen Institute of Biomedical Robot Co., Ltd.(Abrobo), officially received the Class III Medical Device Registration Certificate from China's National Medical Products Administration NMPA. With its unique PANVIS COF® catheter-on-finger control system and multi-device coordination platform, the PANVIS-A™ preserves the natural feel of manual operations while empowering surgeons with sub-millimeter accuracy. This enhanced control makes complex procedures more fluid and precise. The PANVIS-A™ Neurovascular Interventional Robotic System also introduces a remote-control interface, freeing surgeons from the burden of heavy lead aprons and radiation exposure, enhancing both the safety and comfort of the entire surgical process. This innovative design received high praise from attending doctors and has inspired many healthcare professionals to envision a future operating room that is more intelligent, more comfortable, and safer. Independent Innovation: Driving the Evolution of Domestic High-End Medical Equipment For years, the high-end medical device market in China has been dominated by foreign brands. Abrobo is committed to fostering the development of domestic medical equipment through independent innovation. The PANVIS series of Pan-vascular interventional robotic systems, a flagship achievement of Abrobo, represents a major breakthrough in technological accumulation and innovation by China enterprises. With its core technology based on independently developed intellectual property, these series fill a critical gap in the field of vascular interventional robotic systems in China, further enhancing the nation's competitiveness in the global medical device market. Professor Guo Shuxiang, Chairman & Founder of Abrobo, and Foreign Academician of the Japanese Academy of Engineering, stated that Abrobo's mission is to meet ever-changing market needs and address industry challenges through continuous innovation. The company strives to advance technologies through collaboration, bringing together experts from various fields. With this focus, Abrobo aims to make vascular interventional robotic system smarter and establish new industry benchmarks for excellence. Aligning with National Development Strategies: Shaping the Future of Healthcare At the Oriental Conference of Interventional Neurovascology (OCIN 2024), Professor Liu Jianmin, Academician Ge Junbo and Guo Shuxiang each delivered speeches. In their addresses, all three experts emphasized a shared pursuit: in the face of ever-evolving clinical demands and pressing industry challenges, the collective goal is to better safeguard patient health and well-being in this rapidly advancing era of medical technology. The development and market introduction of vascular interventional robotic system represents a successful interdisciplinary endeavor. We look forward to deepening our collaboration in the future and continually advancing technological progress and innovation. The World's First Live Broadcast of Remote Cerebrovascular Interventional Surgery Animal Experiment: Bridging Regions with Technology and Infinite Possibilities On October 26th at the conference, Abrobo successfully completed the world's first live broadcast of an animal experiment for remote interventional neurosurgery, including aneurysm embolization and basilar artery stent implantation. Professor Zhang Yongxin, part of Professor Liu Jianmin's team, conducted the remote operation from outside the operating room using the control interface of the interventional robotic system. He demonstrated complex neurosurgical techniques, particularly the aneurysm embolization, showcasing how Abrobo's interventional robotic system enabled precise deployment of the spring coils for the embolization treatment. Following this, the procedure transitioned to the basilar artery intracranial stenting, which was successfully completed with the assistance of the robotic system. This experiment not only highlighted the robotic system's ability to tackle the challenges associated with complex cerebrovascular surgeries but also overcame the issues of latency and precision control inherent in remote operations, achieving sub-millimeter precision. The PANVIS Star, with its coordinated multi-instrument driving and precise control technologies, confirmed the adaptability of robotic applications across various neuro-interventional procedures. The success of remote surgery not only signifies a technological advancement but also underscores the boundless potential for shared medical resources. For regions with limited healthcare access, remote interventional procedures promise to deliver services comparable to those found in major cities. This experiment showcased China's robust capabilities in the independent research and development of advanced medical equipment and offered new solutions to the global challenge of unequal healthcare resource distribution, embodying a vision where technology makes the future of healthcare accessible. As a trailblazer in vascular interventional robotic systems, Abrobo has continuously upheld the philosophy of integrating medicine and engineering. By identifying key opportunities in clinical practice and pushing the boundaries of core technologies, the company seeks to address critical needs in vascular interventions and elevate product excellence. Abrobo's growth aligns not only with the national "Healthy China" strategy but also actively responds to the "Innovation-Driven Development" policy. As a company powered by independent intellectual property, Abrobo is accelerating the transformation of China's medical device industry towards high-end, international standards, thereby playing a crucial role in enhancing the industry's overall competitiveness. With continuous government investment and policy support in high-end medical equipment, enterprises like Abrobo are helping to boost China's global influence in healthcare. Their core products not only provide reliable equipment for the domestic healthcare system but also offer innovative solutions for the global medical community. Abrobo's efforts in independent innovation are not just about bridging technological gaps within the domestic market but also about exploring equitable distribution of medical resources worldwide. As remote surgical technologies continue to evolve and become widely accessible, we look forward to seeing more Chinese enterprises make their mark on the global medical stage. Together, they will drive the vision of making healthcare accessible to all, ensuring that every patient receives high-quality care, and contributing wisdom and strength to global healthcare initiatives.
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- Recently, Kaiyi Healthcare has made significant strides across its network of hospitals. In July, Wuxi Kaiyi Hospital launched a new emergency response substation connected to China's '120' emergency medical services (EMS)—a system akin to '911' in the US or '999' in the UK—within its facilities. In August, Jiaxing Kaiyi Hospital partnered with GE Healthcare to introduce innovative health testing technology. In addition, Shanghai Kaiyuan Orthopaedics Hospital, in collaboration with the Orthopaedics Branch of the China International Exchange and Promotive Association for Medical and Health Care, will host the 2024 Shanghai Kaiyuan Hip Symposium in September. CEO Peter Wang highlighted, "These initiatives not only underscore Kaiyi Healthcare's role as a pioneer in the modern healthcare service industry but also craft a future blueprint that is patient-centered, technology-driven, and service-focused. This vision aligns perfectly with Kaiyi Healthcare's relentless pursuit of excellence." Kaiyi Healthcare CEO Peter Wang Creating a Patient-Centered Healthcare Network Spanning Multiple Cities From its inception, Kaiyi Healthcare has carved a unique path in healthcare. Originated as a joint venture between Columbia Pacific Management (CPM) in the US and Sheares Healthcare in Singapore, Columbia China gained further momentum in April 2020 when Swire collaborated with CPM to co-invest in the JV. To address the specific needs of the Chinese healthcare market, Kaiyi Healthcare has spun off from Columbia China to grow independently. Based in Shanghai, Kaiyi Healthcare has expanded its reach to establish and manage several medical institutions in cities such as Wuxi and Jiaxing. The company provides high-quality medical services that meet the health needs of the general public, alongside personalized and customized medical services for affluent individuals. Currently, Kaiyi Healthcare manages the specialized hospital Shanghai Kaiyuan Orthopaedics Hospital, and two robust general hospitals: Wuxi Kaiyi Hospital and Jiaxing Kaiyi Hospital. Throughout its development, Kaiyi Healthcare has remained committed to a patient-centered mission to provide patients and their families with better medical care. By establishing a comprehensive healthcare network and introducing cutting-edge medical technologies, Kaiyi Healthcare aims to deliver professional, personalized, and high-quality medical services, fulfilling its vision to become the preferred healthcare provider for Chinese consumers. Building Core Competitiveness with a Multifaceted Approach to Innovation "2024 marks a significant year for Kaiyi Healthcare as it ushers in a new stage of development and leapfrog growth for the three hospitals under our umbrella," said the Kaiyi Healthcare CEO, Mr. Peter Wang. Developing Disciplinary Competence through Localization In terms of building disciplinary competency, Kaiyi Healthcare emphasizes local adaptation, gaining deep insights into the geographical characteristics of the Yangtze River Delta region and the needs of the local population. By aligning market demand with the medical expertise of its hospitals, the company adopts an approach that emphasizes core areas of medical practice alongside unique specialized services to address the diverse needs of patients in the region. Shanghai Kaiyuan Orthopaedics Hospital, for instance, has deployed an innovative integrated diagnosis and treatment system for orthopaedic surgery and rehabilitation. The system specializes in spine, joint, and sports medicine, while also pioneering distinctive disciplines in hip preservation and minimally invasive orthopaedics. Kaiyuan continues to break new ground in medical technology, successfully implementing robot-assisted surgeries and 3D digital printing technology. In doing so, the hospital strives to provide patients with an exceptional healthcare experience through professional technologies and comprehensive services. Wuxi Kaiyi Hospital has further expanded its influence in the cardiovascular field by attracting top-tier talent and leveraging its advanced imported medical equipment and cath lab. The hospital is actively developing new, cutting-edge approaches to cardiac interventions and intravascular ultrasound (IVUS), with the goal of establishing its cardiology department as a leading municipal specialty in Wuxi City. Jiaxing Kaiyi Hospital continues to enhance its pediatric specialties, focusing on sub-specialties within pediatric internal medicine. The hospital plans to launch pediatric night outpatient clinics and pediatric ward services in the fourth quarter of 2024 to better meet clinical needs. Enhancing Service Efficiency with Operational Excellence Mr. Peter Wang indicated, "In the healthcare industry, time is equivalent to a race against life, and every moment is critical. As a result, efficient operation is key to improving the quality of healthcare services and is the cornerstone of achieving sustainable development." Kaiyi Healthcare has fully integrated the modern lean management philosophy into all aspects of hospital operations and management. By reshaping business processes, optimizing resource allocation, and strengthening value chain management, the company has enhanced the quality of healthcare services while reducing patient wait time and healthcare costs. In 2024, Kaiyi Healthcare has made significant progress in diversifying patient sources and business areas while effectively controlling operational costs and optimizing resource efficiency. Notable initiatives include the online patient operations at Shanghai Kaiyuan Orthopaedics Hospital, the 120 EMS at Wuxi Kaiyi Hospital, and the expansion of VIP expatriate clients at Jiaxing Kaiyi Hospital. These efforts have opened up new possibilities for Kaiyi's business model. Optimizing Healthcare Experience through Innovation Kaiyi Healthcare is currently at a critical stage of digital transformation. Notably, Jiaxing Kaiyi Hospital has obtained an Internet hospital license, marking a significant milestone in the implementation of Kaiyi Healthcare's initiative for online medical services. Kaiyi Healthcare plans to build a unified digital management system for planning, implementation, and management through the integration of digital technologies. This system will merge online and offline medical resources, break down barriers between disciplines and medical insurance services, and capture comprehensive healthcare data. By leveraging medical large language models, AI, and other advanced technologies, Kaiyi seeks to further enhance the online medical services. "Moving forward, Kaiyi Healthcare will continue to drive technological innovation in areas such as AI-assisted diagnosis, ChatAI-enabled intelligent digital analysis, and digital patient support services, allowing patients to experience the benefits of technology in healthcare," stated Mr. Peter Wang. Creating a Corporate Culture That Prioritizes Patient Care An excellent corporate culture is indispensable for the growth of the company. "Kaiyi Healthcare has built a unique culture centered on Professionalism, Passion, and Target-orientation (PPT)," explained Mr. Peter Wang. Kaiyi Healthcare instills in its healthcare professionals a profound sense of mission—to uphold passion and composure while addressing patient challenges, enhancing medical care for patients and their families, and ultimately delivering a more compassionate medical service experience. This mission has earned Kaiyi Healthcare continuous recognition and gratitude from government entities, as well as patients and their families. Driven by this mission, more medical specialists and industry leaders have joined Kaiyi Healthcare to help advance its technology and disciplines. In 2023, the company's hospitals brought in 13 seasoned clinicians above the associate professor level, and more than 10 additional specialists are anticipated to join in 2024. Committed to a Long-Term Vision in a Growing Healthcare Sector The private healthcare market in the country is poised for substantial growth, presenting a significant opportunity that has bolstered confidence in Kaiyi Healthcare's future development. Recognizing the potential, Kaiyi Healthcare is committed not only to expanding its reach but also to elevating the standards of medical care and service quality. This balanced approach aims to solidify its position in a competitive industry while ensuring sustainable progress. Mr. Peter Wang added, "The future of the medical industry lies in innovation and service. Only through continuous innovation can we meet the growing health needs of patients; only by providing high-quality services can we win their trust and confidence. Looking ahead, Kaiyi Healthcare will continue to uphold a patient-centered service approach, deepen its brand essence, and expand its reach. By continuously optimizing the medical service model and incorporating advanced medical technologies and management concepts, Kaiyi Healthcare is committed to delivering premium, professional medical services to domestic patients and contributing to the realization of a healthy China."
To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank Planning to initiate global multinational clinical projects in digital therapeutics Establishing a future medical system centered around prevention and management... Expanding digital medical services SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- Amid growing concerns about a medical crisis as a result of acute conflict between the government and the medical community due to an increase in the quota of medical school admission, the regular seminar of the Korea Medical Innovation Research Forum (KMIRF) kicked off; experts from various fields of the medical field gathered to prepare for future medical reform. It was held at Andaz Seoul Gangnam on the 17th of April. First ‘Korea Medical Innovation Research Forum’ regular seminar KMIRF was launched last March by experts in various fields of the medical industry, and is co-represented by Dae Hee Kang, former dean of Seoul National University College of Medicine, current president of the Telemedicine Society, and Jong Yoon Lim, former chairman of the Bio Association, registered director of Hanmi Science and chairman of COREE Group. Medical experts who serve as steering and working committee members of each division, including co-representatives Dae Hee Kang and Jong Yoon Lim, gathered and led a heated discussion for medical reform. In addition, the newly elected People Power Party Representatives Cheolsoo Ahn, Soomin Park, and Democratic Party Representative Do-geol Ahn (via video conference) attended and advocated the Forum at the National Assembly level. Co-representative Jong Yoon Lim mentioned the urgency of addressing immediate medical reform in his opening speech and said, "Medical intellectual property rights belong to the country and the people, and in order to improve the country's global competitiveness and future value in medicine, we need to go beyond Healthcare 4.0 and create a national and permanent proposition." "We will definitely propose future medical innovation policies," he said. "We plan to hold regular seminars for KMIRF at least six times a year and frequently put forward future medical innovation policies with the cooperation of experts and policymakers in each field." In his congratulatory address, Rep. Cheolsoo Ahn said, "The paradigm of health care has completely changed through COVID-19, and now, as part of medical reform, we need to establish a 'future-oriented legal system' that recognizes upcoming technological and social changes, and eliminates regulations that may become obstacles in advance." He emphasized, "It is time to play a role in preparing ahead for the future," and added, "I hope that KMIRF will be play a central role for this change." Co-representative Dae Hee Kang emphasized the importance and revitalization of digital healthcare and personalized preventive medicine through a presentation on the topic of 'Future Medicine and Digital Healthcare', as well as laying out the purpose and role in the establishment of KMIRF along with future goals. He also explained the operation plan and said, "We plan to register as an official research group within the National Assembly Secretariat and will fulfill our role as Korea's representative medical think tank." Industrial Division Director Mahn Soon Hwang gave a presentation on 'Bio-Industry Trends' and emphasized the importance of the country, companies, and investments for the development of the bio-ecosystem and medical reform. In addition, a free discussion was commenced in relation to digital health, especially digital therapeutics, as with new therapeutics. It was suggested that regulatory bodies should be able to determine the price and fee structure that will compensate private companies for their enormous investment in clinical research at the time of approval, and came to a consensus that the tone should be set globally in which any country applying for clinical trials or regulatory approval should be adequately recompensed according to such profit structure logic. As the first step in accomplishing this vision, we have decided to pursue a project regarding multi-national digital therapeutics' clinical trials around the world. Hee Hwang, CEO of Kakao Healthcare, expressed his encouragement by saying that he deems it as a very timely strategy and said, "As a healthcare expert, I will utilize my expertise to help with the research group's first project." Hong Taek Yong, a professor at Hanyang University (former 1st Vice Minister of Science and Technology), said, "I am looking forward to the role of Hanyang University at a time when innovative policies need to be promoted in order to incorporate the remarkable advancements in science and technology into healthcare, and I will do my best to contribute as a member." Professor In Taek Lim of Catholic University (former Director of the Health and Medical Policy Office of the Ministry of Health and Welfare) said, "In order to effectively respond to the rapidly changing medical environment and technological changes, our medical system must develop into human-centered digital-based medical care, and the launch of KMIRF at this time is critical." "We will strive to ensure that the research committee stands at the center of this," he said. Meanwhile, the KMIRF aims to create a healthcare ecosystem where the government, medical community, companies, and citizens can coexist, establishing a future healthcare system centered around prevention and management, and resolving intergenerational and regional medical service imbalances through digital medicine, and other platforms. It will be a proponent in presenting ways to expand access to medical services. In addition, it plans to serve as a bridge through which medical policymakers and decision-makers can come together to commonly recognize and empathize with the all related policies that are put forth. KMIRF is comprised of policy, human resources, and industry divisions; while Hong Taek Yong, former 1st Vice Minister of Science and ICT, leads the policy division, Yu Mi Seo, former 11th director of the Korea Education and Research Information Service, heads the human resources division, and Mahn Soon Hwang, current CEO of Korea Investment Partners leads the industrial division. First ‘Korea Medical Innovation Research Forum’ regular seminar First ‘Korea Medical Innovation Research Forum’ regular seminar [Appendix] Korea Medical Innovation Research Forum Steering Committee Name Profile Dae Hee Kang Former Dean of Seoul National University College of Medicine / Current President of the Telemedicine Society Jong Yoon Lim Former Chairman of the Bio Association / Current Chairman of COREE Group / Current Internal Director of Hanmi Science Hong Taek Yong Former First Vice Minister of Science and ICT / Current Professor at Hanyang University In Taek Lim Former Director of Health and Medical Policy, Ministry of Health and Welfare / Current Research Professor, Graduate School of Health and Medical Management, Catholic University of Korea Oh Sang Kwon Former Deputy Director of the Ministry of Food and Drug Safety / Current Visiting Professor at Seoul National University Kil Won Kim Current President of Korea Medical Biotechnology Association Yu Mi Seo Former 11th Director of Korea Education and Research Information Service Jong Il Kim Current Dean of Department of Medical Sciences, Seoul National University Yoo Suk Hong Current Dean of College of Engineering, Seoul National University Mahn Soon Hwang Current CEO of Korea Investment Partners Sung Kwan Jung Current Medical Vice Chairman of the Korean Hospital Association / Chairman of the Board of Directors of Our Children's Hospital, Our Children's Medical Foundation Byung Ho Nam Former Professor at Boston University / Current CEO of Herings, Co. Ltd. Hee Hwang Current CEO of Kakao Healthcare Young Shin Lee Current CEO of Seers Technology Sung Jun Han Current CEO of Avixgen, CTO of Dx&Vx
A12 藝術空間
medical innovation
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)